Vanderbilt and Ancora Innovation has launched their second RFP. Ancora is a Deerfield company that will support Vanderbilt’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Ancora will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases.
Deerfield is an investment firm dedicated to advancing healthcare, and to accelerating the translation of research in Vanderbilt faculty laboratories into clinical therapeutics.
The first RFP, initiated last spring, resulted in two funded programs that are well on their way in pre-clinical development.
Through Ancora, Deerfield has committed up to $65 million in initial funding to support promising Vanderbilt translational research. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Ancora projects that show commercial potential. Therapeutic programs of all types are eligible for the collaboration, with particular interest in therapeutic antibody programs.
At a recent Information Session, hosted by CTTC and Ancora, in conjunction with the Vanderbilt Office of the Vice Provost for Research, colleagues from Deerfield spoke about specific features of a project that increase the probability of success in clinical development and that make a project attractive for Ancora. A copy of this presentation is available through the portal for the RFP (see below).
The schedule for the two-stage RFP is as follows:
- RFP Opens: March 14, 2019
- LOI Submissions Due: April 15, 2019
- LOI Responses: June 17, 2019
- Full Proposals Due: July 22, 2019
- Final Selections: September 16, 2019
The RFP portal can be accessed through the link below. Following registration on the RFP portal, a copy of the Information Session slides, Guidelines for the LOI, and a summary of the Collaboration Details can be reviewed.